Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Yoga vs Health Education for Persistent Post-COVID Fatigue

Official title: Randomized Multicenter Clinical Trial: Yoga Versus Health Education for the Treatment of Persistent Fatigue in Patients With Post COVID-19 Syndrome

Run by University Hospital Tuebingen · NCT05890599 · Data updated 2026-11-12

This trial will test whether adding a structured yoga program or health education to routine care helps reduce persistent fatigue in adults who had COVID-19.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment100 (estimated)
SponsorUniversity Hospital Tuebingen
Academic / other
Locations1 site (Stuttgart)
StatusRecruiting
StartedJune 10, 2023
Main results expectedDecember 31, 2025
Study endsMarch 31, 2026
Registry record updatedJuly 10, 2025
Trial IDNCT05890599 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–65 with a confirmed COVID-19 infection at least 12 weeks earlier who report ongoing fatigue (Chalder score ≥4) and can participate in yoga are ideal candidates.

Probably not a fit

People whose fatigue is clearly due to other medical conditions, who have physical limitations preventing yoga, who are pregnant or breastfeeding, or who already practice yoga regularly are unlikely to benefit from or qualify for this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional trial compares a structured yoga program plus routine care with health education plus routine care in adults with persistent fatigue after COVID-19. Eligible participants are 18–65 years old with confirmed prior COVID-19, at least 12 weeks of ongoing symptoms, and a Chalder Fatigue Scale score ≥4, while those with other medical causes of fatigue, significant physical limitations, pregnancy/breastfeeding, or current yoga practice are excluded. Interventions are delivered in person at the trial site with short- and medium-term follow-up to measure changes in fatigue. The primary outcome is change in fatigue severity using the Chalder Fatigue Scale, with likely secondary measures of function and quality of life.

Why it matters

Potential benefit: If successful, this could provide a low-risk, non-drug option to reduce persistent fatigue after COVID-19.

How similar studies have gone: Similar mind–body programs and yoga have shown modest benefits for chronic and cancer-related fatigue in small trials, but high-quality evidence specific to post‑COVID fatigue is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Confirmed COVID-19 diagnosis
* Follow-up symptoms of ≥ 12 weeks
* Persistent fatigue (scores ≥4 on the binomial Chalder Fatigue Scale).
* Self-assessment that fatigue was a consequence of COVID-19 disease
* Age 18-65 years

Exclusion Criteria:

* Chronic medical conditions or regular use of medications associated with fatigue
* Indication of health cause of fatigue other than post-COVID.
* Indication of other factors as the main cause of fatigue
* Physical limitations that do not allow participation in the yoga intervention
* Pregnancy, breastfeeding
* Concurrent participation in other clinical trials
* Current yoga practice

Where it's running

  • Bosch-Health-Campus
    Stuttgart, Germany
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.